The etiopathogenesis of atopic dermatitis: barrier disruption, immunological derangement, and pruritus
Open accessThe DOI matches its Crossref record; 215 of the 215 references it cites were found in a registry or an index.
Abstract
Atopic dermatitis (AD) is a common chronic skin inflammatory disorder characterized by recurrent eczema accompanied by an intractable itch that leads to an impaired quality of life. Extensive recent studies have shed light on the multifaceted pathogenesis of the disease. The complex interplay among skin barrier deficiency, immunological derangement, and pruritus contributes to the development, progression, and chronicity of the disease. Abnormalities in filaggrin, other stratum corneum constituents, and tight junctions induce and/or promote skin inflammation. This inflammation, in turn, can further deteriorate the barrier function by downregulating a myriad of essential barrier-maintaining molecules. Pruritus in AD, which may be due to hyperinnervation of the epidermis, increases pruritogens, and central sensitization compromises the skin integrity and promotes inflammation. There are unmet needs in the treatment of AD. Based on the detailed evidence available to date, certain disease mechanisms can be chosen as treatment targets. Numerous clinical trials of biological agents are currently being conducted and are expected to provide treatments for patients suffering from AD in the future. This review summarizes the etiopathogenesis of the disease and provides a rationale for choosing the novel targeted therapy that will be available in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–215 of 215
Bjerkan, L., Sonesson, A., & Schenck, K. (2016) · Pharmaceuticals · doi:10.3390/ph9030041 · Cited by 40 · cited 1×
“In contrast, the long form predominates and possesses proinflammatory activity under inflammatory states, such as in the lesional skin of AD [128, 130].”
BackgroundSagita Moniaga, C., & Kabashima, K. (2011) · Inflammation & Allergy - Drug Targets · doi:10.2174/187152811798104881 · Cited by 37 · cited 1×
“Interestingly, IL-17A is detected in the AD-like dermatitis of flaky tail mice [42, 46, 113].”
BackgroundSelf-citationCutaneous dendritic cells in allergic inflammation
Gros, E., & Novak, N. (2012) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2012.03964.x · Cited by 37 · cited 2×
“DCs are professional antigen-presenting cells that capture antigens, allergens, and microbes, to prime naïve T cells into immunogenic or tolerogenic subsets, and act as a bridge between innate and adaptive immunity [84].”
BackgroundLee, H.-J., Lee, N. R., Kim, B., Jung, M., Kim, D. H., Moniaga, C. S., Kabashima, K., & Choi, E. H. (2016) · Experimental Dermatology · doi:10.1111/exd.13144 · Cited by 36
Self-citationAmano, W., Nakajima, S., Yamamoto, Y., Tanimoto, A., Matsushita, M., Miyachi, Y., & Kabashima, K. (2016) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2016.09.007 · Cited by 35 · cited 1×
“Moreover, the JAK inhibitor can inhibit IFN-γ, IL-13, and IL-17A production from antigen-specific T cells and decrease differentiation and proliferation of effector memory T cells in the draining lymph nodes in the sensitization phase of a murine contact hypersensitivity (CHS) model [201].”
BackgroundSelf-citationRoles of basophils and mast cells in cutaneous inflammation
Otsuka, A., Nonomura, Y., & Kabashima, K. (2016) · Seminars in Immunopathology · doi:10.1007/s00281-016-0570-4 · Cited by 33
Self-citationHonda, T., & Kabashima, K. (2014) · Allergology International · doi:10.1016/j.alit.2014.08.002 · Cited by 29 · cited 3×
“PGD2, presumably from mast cell degranulation, also induction of ILC2 Th2 cytokine production.”
BackgroundSelf-citationVasilopoulos, Y., Sharaf, N., di Giovine, F., Simon, M., Cork, M. J., Duff, G. W., & Ahnini, R. T. (2010) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2010.11.013 · Cited by 22
Otsuka, A., Honda, T., Doi, H., Miyachi, Y., & Kabashima, K. (2010) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2010.10083.x · Cited by 21 · cited 1×
“IL-31 is an important mediator of both itch and inflammation [186, 187].”
BackgroundSelf-citationWatcharanurak, K., Nishikawa, M., Takahashi, Y., Kabashima, K., Takahashi, R., & Takakura, Y. (2012) · Gene Therapy · doi:10.1038/gt.2012.69 · Cited by 15
Self-citationDecreased Filaggrin Level May Lead to Sweat Duct Obstruction in Filaggrin Mutant Mice
Rerknimitr, P., Tanizaki, H., Yamamoto, Y., Amano, W., Nakajima, S., Nakashima, C., Nonomura, Y., Wititsuwannakul, J., Miyachi, Y., Otsuka, A., et al. (2016) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.07.036 · Cited by 10 · cited 1×
“These findings suggest that FLG may also contribute to the integrity of the acrosyringeal wall [55].”
BackgroundSelf-citationKabashima, K., Furue, M., Hanifin, J. M., Pulka, G., Mlynarczyk, I., Wollenberg, A., Galus, R., Mihara, R., Ethoh, T., & Ruzicka, T. (2016) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.06.022 · Cited by 8
Self-citationMitsuishi, T., Kabashima, K., Tanizaki, H., Ohsawa, I., Oda, F., Yamada, Y., Halifu, Y., Kawana, S., Kato, T., & Iida, K. (2011) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2011.05.007 · Cited by 7
Self-citationSkin tape stripping and cheek swab method for a detection of filaggrin
Egawa, G., Doi, H., Miyachi, Y., & Kabashima, K. (2013) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2012.12.004 · Cited by 4 · cited 2×
“In addition, the derangement in proteases required for profilaggrin and Flg processing also gives rise to impairment of the skin barrier and SC dehydration, as observed in mice deficient in CAP1 [21], SASPase [22], and caspase 14 [24].”
BackgroundSelf-citationSevere atopic dermatitis accompanied by autoimmune retinopathy
Nomura, T., Kayama, T., Okamura, E., Ogino, K., Uji, A., Yoshimura, N., Kikuchi, T., Fujisawa, A., Tanioka, M., Miyachi, Y., et al. (2013) · European Journal of Dermatology · doi:10.1684/ejd.2013.1994 · Cited by 2 · cited 1×
“Moreover, there are increasing evidence that AD is associated with systemic diseases and may be considered as a systemic disorder [9, 10].”
BackgroundSelf-citation
Cited by
Pathophysiology of atopic dermatitis: Clinical implications
Kim, J., Kim, B. E., & Leung, D. Y. M. (2019) · Allergy and Asthma Proceedings · doi:10.2500/aap.2019.40.4202 · Cited by 635
“A subset of sensory neurons that express histamine H1 receptor and histamine H4 receptor is activated by histamine, which can cause itch as well as allergic inflammation.(57) H1 antihistamines have been widely used for the treatment of itch due to urticaria, but its effects are limited in the treatment of chronic itch…”
BackgroundAtopic dermatitis: an expanding therapeutic pipeline for a complex disease
Bieber, T. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00266-6 · Cited by 623
Type 2 immunity in the skin and lungs
Akdis, C. A., Arkwright, P. D., Brüggen, M.-C., Busse, W., Gadina, M., Guttman‐Yassky, E., Kabashima, K., Mitamura, Y., Vian, L., Wu, J., et al. (2020) · Allergy · doi:10.1111/all.14318 · Cited by 560
Self-citationType 2 immunity in allergic diseases
Ogulur, I., Mitamura, Y., Yazici, D., Pat, Y., Ardicli, S., Li, M., D’Avino, P., Beha, C., Babayev, H., Zhao, B., et al. (2025) · Cellular & Molecular Immunology · doi:10.1038/s41423-025-01261-2 · Cited by 362
Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis
Silverberg, J. I., Guttman-Yassky, E., Thaçi, D., Irvine, A. D., Stein Gold, L., Blauvelt, A., Simpson, E. L., Chu, C.-Y., Liu, Z., Gontijo Lima, R., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2206714 · Cited by 345
Metadata
- Authors
- Rerknimitr, P., Otsuka, A., Nakashima, C., & Kabashima, K.
- Affiliations
- Chulalongkorn University (TH)
- Kyoto University (JP)
- Agency for Science, Technology and Research (SG)
- Corresponding author
- Otsuka, Atsushi
- Kabashima, Kenji
- Venue
- Inflammation and Regeneration
- Published
- 2017-06-05
- Volume
- 37
- Issue
- 1
- Pages
- 14-14
- ISSN
- 1346-8022 (ISSN-L)
- 1880-8190
- PMC
- PMC5725646
- OpenAlex
- W2623738179
- Cited by
- 187
- References
- 215
- Citations by year
- 2026: 15 · 2025: 21 · 2024: 29 · 2023: 18 · 2022: 19 · 2021: 30 · 2020: 21 · 2019: 22 · 2018: 12
- FWCI
- 2.69
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Inflammation and Regeneration (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Ministries of Education, Culture, Sports, Science and Technology
- the Japan Agency for Medical Research and Development (AMED)
- Ministry of Health, Labour and Welfare Sciences
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Dermatology › Contact Dermatitis and Allergies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Keywords
- atopic dermatitis, etiopathogenesis, skin barrier dysfunction, filaggrin, stratum corneum, tight junctions, pruritus, central sensitization, pruritogens, skin inflammation, biologic therapy, targeted therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.